Patent intelligence · US
US 12128048
Combination therapies using PRMT5 inhibitors for the treatment of cancer
Combination therapies using PRMT5 inhibitors for the treatment of cancer
Patent details — US 12128048
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 29, 2024
- Expiration
- Oct 24, 2044
- Applicant
- Mirati Therapeutics, Inc.
- Claims
- 16
- CPC classes
- A61K, A61K31/416, A61K31/502, A61K31/517
Quick answer
US 12128048 (Combination therapies using PRMT5 inhibitors for the treatment of cancer) is held by Mirati Therapeutics, Inc.. Status: granted. Granted Oct 29, 2024. Expires Oct 24, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Mirati Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61K, A61K31/416, A61K31/502, A61K31/517, A61K31/519, A61K45/06
More from Mirati Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12421228
Naphthyridine derivatives as PRC2 inhibitors
granted -
US 12421253
Tetrahydropyridopyrimidine pan-KRas inhibitors
granted -
US 12414911
Topical compositions and methods of use
granted -
US 12412764
Substrate-accommodating container
granted -
US 12398154
Azaquinazoline pan-KRas inhibitors
granted -
US 12383503
Adagrasib solid pharmaceutical compositions
granted -
US 12377101
Combination therapies
granted -
US 12371435
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
granted
Frequently asked questions
What is US patent 12128048?
US 12128048 (Combination therapies using PRMT5 inhibitors for the treatment of cancer) is held by Mirati Therapeutics, Inc.. Status: granted. Granted Oct 29, 2024. Expires Oct 24, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12128048?
Mirati Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 308 pharmaceutical patents for this assignee.
When does US 12128048 expire?
Our index shows an expiration date of Oct 24, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.